Evofem Biosciences logo
Evofem Biosciences EVFM
report update icon

Quarterly report 2026-Q1
added 05-15-2026

Evofem Biosciences Revenue | EVFM

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Evofem Biosciences

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
20.2 M 19.4 M 18.2 M 16.8 M 8.24 M 446 K - - - - - - - 100 K -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
20.2 M 100 K 11.9 M

Quarterly Revenue Evofem Biosciences

2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
899 K 4.95 M 4.82 M 845 K - 4.5 M 4.16 M 3.6 M - 5.11 M 2.46 M 5.81 M - 6.37 M 6.03 M 4.25 M - 1.71 M 1.86 M 1.1 M - 278 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
6.37 M 278 K 3.46 M

References

  1. Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer Revenue Price % 24h Market Cap Country
FibroGen FibroGen
FGEN
6.44 M - - $ 889 M usaUSA
Homology Medicines Homology Medicines
FIXX
53.7 M - 0.77 % $ 53.4 M usaUSA
Amicus Therapeutics Amicus Therapeutics
FOLD
634 M - - $ 4.47 B usaUSA
Frequency Therapeutics Frequency Therapeutics
FREQ
6.39 M - - $ 528 M usaUSA
GlycoMimetics GlycoMimetics
GLYC
10.8 M - 9357.83 % $ 1.01 B usaUSA
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
14.6 M - 1.35 % $ 17.8 M chinaChina
KalVista Pharmaceuticals KalVista Pharmaceuticals
KALV
49.1 M - - $ 1.45 B britainBritain
KemPharm KemPharm
KMPH
106 M - -0.34 % $ 200 M usaUSA
Kezar Life Sciences Kezar Life Sciences
KZR
7 M - - $ 53.3 M usaUSA
Lixte Biotechnology Holdings Lixte Biotechnology Holdings
LIXT
200 K - - $ 63.4 M usaUSA
Magenta Therapeutics Magenta Therapeutics
MGTA
2.04 M - -7.74 % $ 41.6 M usaUSA
NovaBay Pharmaceuticals NovaBay Pharmaceuticals
NBY
9.78 M - - $ 11.3 M usaUSA
OncoCyte Corporation OncoCyte Corporation
OCX
4.06 M - 17.22 % $ 355 K usaUSA
Onconova Therapeutics Onconova Therapeutics
ONTX
2.79 M - -0.47 % $ 21 M usaUSA
Opthea Limited Opthea Limited
OPT
25 K - - $ 1.2 B australiaAustralia
Pieris Pharmaceuticals Pieris Pharmaceuticals
PIRS
42.8 M - -15.58 % $ 1.22 B germanyGermany
Plus Therapeutics Plus Therapeutics
PSTV
5.21 M - - $ 301 M usaUSA
Pluristem Therapeutics Pluristem Therapeutics
PSTI
1.02 M - -1.9 % $ 33.3 M israelIsrael
Qualigen Therapeutics Qualigen Therapeutics
QLGN
4.98 M - 5.59 % $ 1.16 M usaUSA
Qilian International Holding Group Limited Qilian International Holding Group Limited
QLI
37.9 M - -6.08 % $ 184 M chinaChina
Cassava Sciences Cassava Sciences
SAVA
41.1 M - - $ 110 M usaUSA
Selecta Biosciences Selecta Biosciences
SELB
2.8 M - -8.69 % $ 126 M usaUSA
Sangamo Therapeutics Sangamo Therapeutics
SGMO
39.6 M - - $ 50.4 M usaUSA
Salarius Pharmaceuticals Salarius Pharmaceuticals
SLRX
1.84 M - - $ 2.64 M usaUSA
Sonnet BioTherapeutics Holdings Sonnet BioTherapeutics Holdings
SONN
1 M - - $ 826 K usaUSA
Synlogic Synlogic
SYBX
8 K - - $ 7.07 M usaUSA
Vallon Pharmaceuticals Vallon Pharmaceuticals
VLON
100 K - -6.47 % $ 5.76 M usaUSA
Vaxart Vaxart
VXRT
39.2 M - -25.06 % $ 46.3 M usaUSA
XOMA Corporation XOMA Corporation
XOMA
52.1 M - - $ 485 M usaUSA
Windtree Therapeutics Windtree Therapeutics
WINT
198 K - - $ 26.8 M usaUSA
Trean Insurance Group Trean Insurance Group
TIG
303 M - - $ 316 M usaUSA
SQZ Biotechnologies Company SQZ Biotechnologies Company
SQZ
21.5 M - 57.95 % $ 12.8 M usaUSA
Brickell Biotech Brickell Biotech
BBI
8.01 M - -5.38 % $ 6.06 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
455 K - - $ 8.42 M usaUSA
Generation Bio Co. Generation Bio Co.
GBIO
19.9 M - - $ 344 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
1.66 M - - $ 25.3 M usaUSA
MEI Pharma MEI Pharma
MEIP
65.3 M - 10.43 % $ 20.5 M usaUSA
Palatin Technologies Palatin Technologies
PTN
8.83 M - - $ 13 M usaUSA